Clinical Trials on Cystic Fibrosis Related Bone Disease

Total 71769 results

Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
University Hospital, Brest

Active, not recruiting

Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis (BEACH)

Cystic Fibrosis

France
Paul Beringer
Paratek Pharmaceuticals Inc

Completed

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Cystic Fibrosis

United States
University of New Mexico

Completed

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF

Cystic Fibrosis

United States
Chris Goss
University of Washington; University of Arkansas; Harvard University; Cystic Fibrosis...

Completed

Observational Study Comparing Home to Office Spirometry (OUTREACH)

Cystic Fibrosis

United States
Hospices Civils de Lyon

Active, not recruiting

Evolution of the 6-minute Walk Test in Patients Treated With ELEXACAFTOR / TEZACAFTOR / IVACAFTOR (TEMETI)

Cystic Fibrosis

France
University of Virginia

Completed

Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis

Cystic Fibrosis

United States
Dixie Durham

Completed

Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis (FI)

Cystic Fibrosis
Yale University

Completed

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

Cystic Fibrosis

United States
Bayer
Merck Sharp & Dohme LLC

Terminated

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Cystic Fibrosis

Germany, United States, France, Canada, Belgium, Netherlands, United Kingdom
Children's Hospital Medical Center, Cincinnati

Active, not recruiting

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Cystic Fibrosis

United States
Children's Hospital Medical Center, Cincinnati
The Hospital for Sick Children; University of Wisconsin, Madison; University...

Active, not recruiting

Hyperpolarized Imaging for New Treatments (HyPOINT)

Cystic Fibrosis

United States, Canada
Children's Hospital Medical Center, Cincinnati

Active, not recruiting

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Belgium, Spain, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
University of Pittsburgh
Cystic Fibrosis Foundation

Completed

Inhaled Bicarbonate Therapy in Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Institut de Recherches Cliniques de Montreal

Completed

The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis (SNACK_CF)

Cystic Fibrosis

Canada
Gazi University

Completed

Upper Extremity Exercise Capacity, Muscle Oxygenation, Balance in Patients With Cystic Fibrosis

Cystic Fibrosis

Turkey
University Hospital, Lille

Completed

Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis (EFX)

Cystic Fibrosis

France
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
University of Washington
Cystic Fibrosis Foundation

Completed

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

Cystic Fibrosis

United States
University of Alabama at Birmingham
Cystic Fibrosis Foundation

Completed

Clinical Effort Against Smoke Exposure in Cystic Fibrosis (CEASE-CF)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
National Jewish Health

Completed

Phase II Study of Digitoxin to Treat Cystic Fibrosis

Cystic Fibrosis

United States
Mylan Inc.

Completed

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

Cystic Fibrosis

United States, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Assistance Publique - Hôpitaux de Paris
Societe Francaise de la Mucoviscidose; Effi-Stat

Completed

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) (ORKAMBI)

Cystic Fibrosis

France
Royal Brompton & Harefield NHS Foundation Trust
National Institute for Health Research, United Kingdom

Completed

Improving Outcome Measures For Adult CF ACT Trials

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Santhera Pharmaceuticals

Completed

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

Cystic Fibrosis

Germany
University Hospital, Lille

Terminated

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis (TOBRAMUC)

Cystic Fibrosis

France
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United Kingdom, United States, France, Ireland
Hospices Civils de Lyon

Completed

Cystic Fibrosis Adherence Study (KINOBS)

Cystic Fibrosis

France
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) (CLEAN-CF)

Cystic Fibrosis

United States
Boston Children's Hospital

Completed

Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Steven M Rowe

Completed

G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) (GOAL- e2)

Cystic Fibrosis

United States
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Rush University Medical Center

Completed

Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS)

Cystic Fibrosis

United States
NovaBiotics Ltd.
Agility Clinical, Inc.; PSR Group B.V.

Completed

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations (CARE-CF1)

Cystic Fibrosis

United States, United Kingdom, Italy
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Evaluation of a Behavioural Intervention Using App Technology in CF (EAT-CF)

Cystic Fibrosis

United Kingdom
University of Colorado, Denver
Cystic Fibrosis Foundation; Colorado Clinical & Translational Sciences Institute

Completed

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Cystic Fibrosis

United States
Carmel Medical Center

Completed

Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.

Cystic Fibrosis
Novartis Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Liminal BioSciences Ltd.

Terminated

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Cystic Fibrosis

Canada
University of Miami
University of Alabama at Birmingham; University of Kansas Medical Center; Children... and other collaborators

Terminated

Losartan and Inflammation in Cystic Fibrosis

Cystic Fibrosis

United States

Clinical Trials on Cystic Fibrosis Related Bone Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations